Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

March 25, 2015

BIO Asia International Conference Presentation Slides Available

Slides from Provectus' presentation at the 12th Annual BIO Asia International Conference will be available at 2:30am EDT on March 25, 2015.

March 25, 2015

BioCentury Reports Start of Enrollment for Phase 2 PH-10 Method of Action Study

An article appearing recently in BioCentury reports that enrollment has begun for the Phase 2 trial studying PH-10's method of action.

March 25, 2015

BioCentury Reports Completion of Enrollment for PV-10 Phase 1 Method of Action Study

An article appearing recently in BioCentury reports on the completion of enrollment for the Phase 1 trial studying PV-10's method of action.

March 17, 2015

Provectus gets US patent entitled "Topical medicaments and methods for photodynamic treatment of disease"

Pharmabiz.com covers news that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 8,974,363 to Provectus. The new patent, entitled "Topical medicaments and methods for photodynamic treatment of disease," provides detailed protection of the company's investigational dermatological drug PH-10.

March 13, 2015

Provectus Biopharmaceuticals Invites You to a Panel Discussion

Provectus will host a panel discussion on Thursday, April 9, 2015 from 5:00 - 6:30 PM EDT. The discussion will take place at The Harvard Club of New York City, 35 West 44 Street in the Cambridge Room. Meeting will be posted as Provectus Biopharmaceuticals, Inc.

March 12, 2015

Webcast: Conference Call March 12 4:00 PM EDT

Provectus will hold its year-end quarterly business update conference call at 4 p.m. (EDT) to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

March 9, 2015

[Video] Presentation at European Life Science CEO Forum & Exhibition

A video of Peter Culpepper's presentation at the 8th Annual European Life Science CEO Forum & Exhibition on March 3, 2015 is now available.

March 4, 2015

PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3

An article appearing on Medscape discusses the rapid response of PV-10 seen in phase 2 melanoma testing and how this affected the phase 3 trial design.

March 4, 2015

Cityview Magazine Interviews Provectus' CEO Craig Dees, Ph.D.

Cityview Magazine recently interviewed Provectus CEO Craig Dees, Ph.D.

March 2, 2015

Presentation Slides from European Life Science CEO Forum & Exhibition

Slides from Provectus' presentation at the 8th Annual European Life Science CEO Forum & Exhibition on March 3, 2015 are now available.

February 17, 2015

Melanoma News Today Covers Recent Paper on Importance of Intralesional Melanoma Treatment

Melanoma News Today covered a paper recently published in Current Opinion in Oncology entitled "Intralesional therapy for advanced melanoma: promise and limitation".

February 13, 2015

Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper

A recent paper in Current Opinion in Oncology states that despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy.

February 10, 2015

BIO CEO Presentation Available

Slides from Provectus' presentation at the BIO CEO and Investor Conference will be available at 3 pm EDT on February 10, 2015.

February 10, 2015

Provectus Biopharmaceuticals Concludes FDA Meeting for PV-10 Phase 3

A BioMedReports article reports on the recently completed FDA meeting for PV-10 phase 3.

January 29, 2015

Kate's Foundation Covers Grant of PV-10 Synthesis Patent in China

Kate's Foundation has posted news, first appearing on inPharmaTechnologist.com, that the Chinese government has granted Provectus a patent protecting a method of making the active pharmaceutical ingredient (API) in PV-10.

January 29, 2015

Provectus receives Chinese patent application allowance for melanoma drug candidate

Healio reports that Provectus has received allowance from the Chinese Patent Office for an application to protect its synthetic process for producing the small molecule rose bengal, the active pharmaceutical ingredient (API) in PV-10, a melanoma drug candidate.

January 28, 2015

Society for Melanoma Research and American Heart Association Scientific Sessions

In a P&T Community article reporting on the Society for Melanoma Research annual meeting, Dr. Merrick Ross discusses how PV-10's mechanism of action may be synergistic with ipilimumab.

January 27, 2015

China patent gives Provectus green light to find partner for melanoma candidate

in-Pharma Technologist reports that the patent covering synthesis of PV-10 API, recently granted by the Chinese government, enables licensing deals between Provectus and Chinese partners.

January 26, 2015

Dermwire: Novel Synthesis Patent Application Allowed by Chinese Patent Office

Dermwire covers news that the Chinese Patent Office has allowed Provectus' patent application covering the synthesis of PV-10.

January 22, 2015

Video: Plans for a Phase 3 Study of PV-10 in Melanoma

In a video appearing on P&T Community, Dr. Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative and who currently don’t have good treatment options.

more...

PRESS RELEASES

March 20, 2015

Provectus Biopharmaceuticals Will Present at the 12th Annual BIO Asia International Conference Wednesday, March 25, 2015

Provectus announced today that it will present at the 12th Annual BIO Asia International Conference, taking place on March 24th and 25th at the Grand Hyatt in Tokyo, Japan.

March 16, 2015

Provectus Biopharmaceuticals' Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online

Provectus announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA") to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.

March 12, 2015

Provectus Biopharmaceuticals Updates Market on Business Developments

Provectus today provides the market with a business update that addresses several matters.

March 12, 2015

Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office

Provectus announced today that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO).

March 12, 2015

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Results

Provectus today announced its results of operations and financial condition for the fourth quarter and year ended December 31, 2014.

February 24, 2015

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

February 18, 2015

Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition

Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.

February 10, 2015

Provectus Biopharmaceuticals Will Present at 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015

Provectus announced today that it will present at the 17th Annual BIO CEO and Investor Conference on Tuesday, February 10,2015.

February 9, 2015

Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

Provectus announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

February 6, 2015

Provectus Biopharmaceutical's PV-10 Featured in Article by Sanjiv Agarwala in Current Opinion in Oncology

Provectus announced today that an article, entitled "Intralesional therapy for advanced melanoma: promise and limitation," authored by Sanjiv S. Agarwala, MD, has been published in the March issue of Current Opinion in Oncology, now available online.

January 29, 2015

Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis

Provectus announced today that it has opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis.

January 26, 2015

Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.

December 23, 2014

Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online

Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:

December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

November 14, 2014

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.

November 13, 2014

Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online

Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.

November 10, 2014

Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting

Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.

November 6, 2014

Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results

Provectus today announced financial results for the third quarter of 2014.

November 6, 2014

Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.

more...